Concentration and composition dependent aggregation of Pluronic- and Poly-(2-oxazolin)-Efavirenz formulations in biorelevant media.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractMany drugs and drug candidates are poorly water-soluble. Intestinal fluids play an important role in their solubilization. However, the interactions of intestinal fluids with polymer excipients, drugs and their formulations are not fully understood. Here, diffusion ordered spectroscopy (DOSY) and nuclear Overhauser effect spectroscopy (NOESY), complemented by cryo-TEM were employed to address this. Efavirenz (EFV) as model drug, the triblock copolymers Pluronic® F-127 (PF127) and poly(2-oxazoline) based pMeOx-b-pPrOzi-b-pMeOx (pOx/pOzi) and their respective formulations were studied in simulated fed-state intestinal fluid (FeSSIF). For the individual polymers, the bile interfering nature of PF127 was confirmed and pure pOx/pOzi was newly classified as non-interfering. A different and more complex behaviour was however observed if EFV was involved. PF127/EFV formulations in FeSSIF showed concentration dependent aggregation with separate colloids at low formulation concentrations, a merging of individual particles at the solubility limit of EFV in FeSSIF and joint aggregates above this concentration. In the case of pOx/pOzi/EFV formulations, coincident diffusion coefficients for pOx/pOzi, lipids and EFV indicate joint aggregates across the studied concentration range. This demonstrates that separate evaluation of polymers and drugs in biorelevant media is not sufficient and their mixtures need to be studied to learn about concentration and composition dependent behaviour.
CitationJ Colloid Interface Sci. 2022 Jan 15;606(Pt 2):1179-1192. doi: 10.1016/j.jcis.2021.08.040. Epub 2021 Aug 10.
AffiliationHIRI, Helmholtz-Institut für RNA-basierte Infektionsforschung, Josef-Shneider Strasse 2, 97080 Würzburg, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
- <i>In silico</i> bioavailability for BCS class II efavirenz tablets using biorelevant dissolution media for IVIVR and simulation of formulation changes.
- Authors: Silva TMD, Honorio TDS, Chaves MHDC, Duque MD, Cabral LM, Patricio BFC, Rocha HVA
- Issue date: 2021 Aug
- Characterization, <i>in vitro</i> dissolution, and pharmacokinetics of different batches of efavirenz raw materials.
- Authors: Bedor DCG, Bedor NCTC, Neto JGP, José de Alencar Danda L, de Oliveira FM, de Oliveira GHO, Soares Sobrinho JL, Beyssac E, Castro WV, Santana DP
- Issue date: 2021 May
- Polymeric Precipitation Inhibitor Assisted Supersaturable SMEDDS of Efavirenz Based on Experimental Observations and Molecular Mechanics.
- Authors: Singh M, Singh D, Mahajan S, Sheikh BA, Bedi N
- Issue date: 2021
- Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.
- Authors: Date AA, Shibata A, Goede M, Sanford B, La Bruzzo K, Belshan M, Destache CJ
- Issue date: 2012 Dec
- Drug solubilization and delivery from cyclodextrin-Pluronic aggregates.
- Authors: Rodriguez-Perez AI, Rodriguez-Tenreiro C, Alvarez-Lorenzo C, Concheiro A, Torres-Labandeira JJ
- Issue date: 2006 Sep-Oct